Colombo Giancarlo, Orrù Alessandro, Lai Paola, Cabras Claudia, Maccioni Paola, Rubio Marina, Gessa Gian Luigi, Carai Mauro A M
C.N.R. Institute of Neuroscience, Viale Diaz 182, Cagliari (CA), 182 I-09126, Italy.
Mol Neurobiol. 2007 Aug;36(1):102-12. doi: 10.1007/s12035-007-0017-y. Epub 2007 Jul 3.
Several lines of preclinical evidence indicate the ability of the prototypic cannabinoid CB(1) receptor antagonist, rimonabant, to suppress various alcohol-related behaviors, including alcohol drinking and seeking behavior and alcohol self-administration in rats and mice. Together, these data-synthetically reviewed in the present paper-suggest (a) the involvement of the cannabinoid CB(1) receptor in the neural substrate controlling alcohol intake, alcohol reinforcement, and the motivational properties of alcohol and (b) that rimonabant may constitute a new and potentially effective medication for the treatment of alcohol dependence.
多项临床前证据表明，典型的大麻素CB(1)受体拮抗剂利莫那班能够抑制多种与酒精相关的行为，包括大鼠和小鼠的饮酒行为、觅酒行为以及酒精自我给药行为。综合本文所综述的这些数据表明：(a) 大麻素CB(1)受体参与了控制酒精摄入、酒精强化作用以及酒精动机特性的神经基质；(b) 利莫那班可能构成一种治疗酒精依赖的新型且潜在有效的药物。
